Explore our validated service units and standardized botanical research pipelines engineered to accelerate compound validation and industrial deployment.
Navigating shifting phytopharmaceutical supply chains, international compliance convergence, and the rising demand for chemically fingerprinted, clinically substantiated herbal matrices.
The international nutraceutical and pharmaceutical market has fundamentally transitioned away from simple botanical ratios (e.g., 4:1 or 10:1 crude powders) toward quantified active pharmaceutical ingredients (APIs). Global brand owners now require validated markers, known secondary metabolic pathways, and batch-to-batch chromatographic similarity indexes exceeding 95% to satisfy rigorous FDA, EMA, and NMPA regulatory scrutiny.
Biotechnology brand developers increasingly avoid heavy internal capital expenditures by relying on specialized ODM/CDMO botanical organizations. Contract development consolidates rare botanical library screening, analytical chemistry method establishment (HPTLC, HPLC-MS/MS), and clinical validation into one integrated workflow, compressing multi-year product development cycles down to 6 to 12 months.
Cross-border regulatory friction has reached an all-time high with stringent limits on polycyclic aromatic hydrocarbons (PAHs), heavy metals (Pb, Cd, As, Hg), pyrrolizidine alkaloids (PAs), pesticide residues, and aflatoxins. An elite ODM botanical expert manufacturer must integrate high-resolution mass spectrometry and validated clean extraction steps directly within the core pilot line.
Over 14+ years we have executed complex R&D programs for more than 100 leading pharmaceutical manufacturers and TCM hospitals, completing modern medical studies for 83 classic Traditional Chinese Medicine formulas, engineering 22 innovative natural medicines, and establishing quality standards for nearly 400 single herbs.
Phytochemical screening leveraging accumulated proprietary chromatographic libraries. Rapidly identifying target polyphenols, ginsenosides, and active polysaccharides optimized for receptor affinity.
Precision establishment of HPTLC identification plates, gradient HPLC assays, and GC-MS profiling to guarantee quantitative repeatability and non-ambiguous batch identification.
Resolving extraction degradation, solubility barriers, and low bioavailability across scale-up. Fully bridging lab findings into commercial multiton extraction units.
Entrusted contract operations maintained under ironclad non-disclosure protocols. Client formulations, synthetic blueprints, and proprietary extraction routes are never compromised.
Comparing classical extraction paradigms against advanced continuous-flow countercurrent isolation and supercritical clean technologies deployed by modern botanical manufacturing experts.
| Processing Benchmark | Legacy Herbal Extraction Methods | Advanced ODM Botanical CDMO Standards | Commercial & Therapeutic Value |
|---|---|---|---|
| Extraction Matrix & Solvent System | Open hot-water percolation, atmospheric ethanol refluxing | Dynamic countercurrent extraction, subcritical water & Supercritical Fluid CO2 (SFE) | Zero thermal degradation of thermo-sensitive monomers; complete recovery of native terpene profiles. |
| Active Ingredient Isolation | Coarse resin adsorption, non-selective precipitation | Multi-dimensional preparative chromatography & molecular membrane fractional filtration | Purity thresholds elevated from 30% to >98.5% standardized isomer integrity. |
| Residual Solvent & VOC Control | Standard batch evaporation, unpredictable residue variance | Thin-film flash evaporation & vacuum lyophilization under constant closed loop | Meets strict USP <467> and EP limits (Ethanol <5000 ppm; Class 2 solvents undetectable). |
| Standardization Strategy | Single-marker photometric verification (UV-Vis) | Quantitative Analysis of Multi-Components by Single-Marker (QAMS) & LC-MS/MS | Absolute fingerprint congruence preventing economically motivated adulteration. |
| Bioavailability Enhancement | Crude powders with poor gut wall permeability | Liposomal nano-encapsulation, spray-dried cyclodextrin complexes, and self-microemulsifying systems | Up to 8-fold increase in human oral bio-absorption and verified Cmax parameters. |
By leveraging proprietary machine-learning models mapped to cellular receptor pathways, our computational biologists predict the binding affinity of complex plant secondary metabolites, reducing target discovery timelines by 65%.
Integrating metabolomics and genomic barcoding to evaluate raw herbal batches. This ensures unequivocal taxonomic origin authentication, distinguishing true functional cultivars from morphologically similar wild species.
Implementing solvent recycling loops that reclaim 98% of industrial volatile phases. Spent biomass is cleanly repurposed for soil conditioning and zero-carbon thermal energy recuperation.
How our contract manufacturing and analytical validation systems deploy specialized botanical products aligned with North American, European Union, and Asia-Pacific market standards.
Formulated for demanding US dietary supplement brand owners. We construct full toxicology dossiers, subacute 90-day animal data, and genotoxicity packages to substantiate New Dietary Ingredient Notifications (NDIN) and Generally Recognized As Safe (GRAS) independent conclusions.
Compliant with European Monographs and stringent pharmacopoeial regulations. Our plants provide validated quantification of active constituents, clean Pyrrolizidine Alkaloid testing (<1.0 µg/kg), ethylene oxide absence guarantees, and documented history of consumption dossiers.
Powering China's Blue Hat (Health Food) and hospital preparation registrations (56 approvals logged), as well as Japan’s Foods with Function Claims (FFC) and Korea's MFDS Functional Raw Material dossiers through standardized botanical extracts.
Water-soluble, non-staining, hypoallergenic active plant fractions engineered for topical anti-inflammatory, anti-tyrosinase, and barrier-repair formulas, supported by human patch safety assays and keratinocyte cell viability data.
Targeted API isolation under cGMP guidelines to support Investigational New Drug (IND) filings. We furnish detailed CMC documentation, stability profiles (accelerated & real-time), and impurity tracking for pharmaceutical innovators.
Microencapsulated, taste-masked botanical oils, water-dispersible granules, and heat-stable polyphenol complexes capable of surviving pasteurization without active constituent degradation or clouding.
A transparent, stage-gated scientific development protocol ensuring reproducibility, regulatory acceptance, and seamless technical transfer for global clients.
Evaluation of natural materials across climatic zones, geo-origins, and seasonal harvest stages. Phytochemical density mapping establishes optimal raw-material specifications and guarantees long-term supply resilience.
Pilot unit optimization testing parameters: solvent-to-solid ratio, temperature profiles, resin kinetic models, spray-drying thermodynamics, and stability under ICH Q1A guidelines.
Targeted cell culture assays (anti-inflammatory, metabolic, immunomodulating) followed by rodent pharmacokinetics and GLP-compliant toxicological assays (LD50, Ames test, micronucleus).
Small-group proof-of-concept human trials for dietary supplement claims substantiation or full double-blind, placebo-controlled Phase I–IV clinical study designs for botanical drug candidates.
Full commercial production across our integrated facilities. Available output formats: concentrated liquids, micro-milled powders, softgels, two-piece hard capsules, tablets, and effervescent granules.
Supply of complete analytical release dossiers, Certificates of Analysis (COA), validation batches, stability updates, and continuous optimization of commercial active yields.
Over 100 enterprise collaborations across research universities, state pharmaceutical conglomerates, and premier teaching medical centers.
Tongrentang Group
CR Sanjiu Medical
Sunflower Pharma
Livzon Pharma Group
Dihon Pharmaceutical
Golden Throat Group
Yangtze River Pharma
Humanwell Healthcare
Authoritative insights addressing custom contract terms, analytical limits, intellectual property preservation, and scale-up engineering.
Conventional suppliers stock generic botanical commodities with wide compositional variance and basic photometric standardization. As an ODM botanical expert manufacturer, MedGence provides end-to-end preclinical chemistry, manufacturing, and control (CMC) pipelines: screening active molecules, establishing custom chromatographic fingerprints (HPTLC/HPLC/GC), proving safety through in vitro and in vivo models, running clinical trials, and manufacturing finished dosage forms under stringent cGMP conditions.
We evaluate raw herbs across varying harvest months, altitudes, and geographical origins. Through comprehensive HPLC and LC-MS metabolomic mapping, we determine the precise accumulation peak of target secondary metabolites. This data-driven sourcing locks in certified harvest windows and specific regional cultivars, ensuring your commercial batches remain chemically uniform year after year.
We deploy High-Performance Thin-Layer Chromatography (HPTLC) for unequivocal botanical identity confirmation alongside High-Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC) for active substance quantification. Furthermore, our laboratories develop multi-wavelength chromatographic fingerprints and QAMS methods, guaranteeing that adulterants, degraded isomers, or synthetic spikes cannot pass undetected.
We operate strictly under an entrusted research and contract development architecture. All projects are safeguarded by legally binding non-disclosure agreements (NDAs) subject to international jurisdiction. Internal cleanroom teams operate with air-gapped data protocols, and customer recipes, crystallization routes, and patent portfolios remain the absolute, unencumbered intellectual property of the commissioning client.
Yes. In addition to in vitro cytotoxicity, receptor binding, and in vivo toxicological assessments (LD50, acute, sub-chronic, Ames genotoxicity), our clinical department coordinates human trials. This includes randomized, double-blind, placebo-controlled human trials for dietary supplement claim substantiation, as well as formal Phase I to Phase IV clinical study protocols required by national regulatory bodies for botanical drug approvals.
Our contract manufacturing capabilities cover bulk active materials (super-concentrated liquids, vacuum spray-dried powders, active pastes, pure volatile essential oils) and fully packaged consumer-ready finished forms: two-piece vegetarian or gelatin hard capsules, liquid softgels, coated tablets, effervescent granules, functional oral liquids, and cold-water-soluble drink blends.
Initiate your next botanical product development campaign by securing precision analytical and laboratory-scale testing modules directly with our scientists.
Whether you are engineering an innovative phytochemical NDA, securing a substantiated dietary supplement claim, or transferring complex botanical extraction processes to a reliable cGMP facility, our multidisciplinary scientists are ready to assist.
